智通财经网·2025-11-20 09:07Core Viewpoint - Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotech has received inclusion of its independently developed drug, Surulitinib Injection, in the breakthrough therapy designation for the treatment of gastric cancer, marking a significant advancement in the field of PD-1 monoclonal antibodies [1] Group 1: Company Developments - The drug Surulitinib Injection, marketed in China as Hanshuanzhuang®, is an innovative anti-PD-1 monoclonal antibody developed by the company [1] - The inclusion in the breakthrough therapy program indicates a potential expedited development and review process for the drug [1] Group 2: Industry Context - As of the announcement date, there are no approved PD-1 targeted monoclonal antibody drugs for neoadjuvant/adjuvant treatment of gastric cancer globally [1] - According to IQVIA MIDAS™ data, the global sales of PD-1 targeted monoclonal antibody drugs are projected to reach approximately $45.704 billion in 2024 [1]